Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/75042
Campo DC Valoridioma
dc.contributor.authorOjeda, Soledaden_US
dc.contributor.authorPan, Manuelen_US
dc.contributor.authorMartin, Pedroen_US
dc.contributor.authorMazuelos, Franciscoen_US
dc.contributor.authorSuarez de Lezo, Javieren_US
dc.contributor.authorRomero, Miguelen_US
dc.contributor.authorSegura, Joseen_US
dc.contributor.authorPavlovic, Djordjeen_US
dc.contributor.authorMedina, Alfonsoen_US
dc.contributor.authorSuarez de Lezo, Joseen_US
dc.date.accessioned2020-10-27T13:38:00Z-
dc.date.available2020-10-27T13:38:00Z-
dc.date.issued2014en_US
dc.identifier.issn1936-8798en_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/75042-
dc.description.abstractObjectives The goal of this study was to assess the immediate and long-term outcomes in patients undergoing percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) in an unprotected distal left main coronary artery (UDLM).Background PCI for UDLM-ISR can be complex. Limited information is available on procedural and clinical outcomes. Methods Between May 2002 and February 2011, UDLM-ISR after drug-eluting stent implantation was observed in 79 of 1,102 patients (7%). Seventy-five were treated by repeat PCI using a simple approach (balloon/in-stent implantation) or a complex strategy (additional stent/double-stenting technique). A diagnosis of mild or severe restenosis was considered depending on the number of bifurcation segments affected (1 vs. >1). Major adverse cardiac events (MACE) were defined as cardiac death, target lesion revascularization, and myocardial infarction.Results ISR treatment was performed using a simple approach in 44 (58%) patients, and using a complex strategy in 31 (42%). After 46 +/- 26 months, the MACE rate was 22%. Patients treated with a simple approach had a lower incidence of MACE at follow-up compared with patients treated with a complex strategy, regardless of the restenosis extent (mild restenosis: 93% vs. 67%, p < 0.05; severe: 70% vs. 23%, p < 0.05). On Cox regression analysis, diabetes was the only predictor of MACE (hazard ratio [HR]: 4.94; 95% confidence interval [CI]: 1.03 to 23.70; p < 0.05), whereas a simple strategy for ISR treatment was associated with lower risk (HR: 0.25; 95% CI: 0.08 to 0.79; p = 0.02).Conclusions PCI for UDLM-ISR is safe and feasible, with a high rate of procedural success and an acceptable long-term MACE rate. A simple strategy, when applicable, appears to be a good treatment option, associated with a lower event rate at follow-up. (C) 2014 by the American College of Cardiology Foundationen_US
dc.languageengen_US
dc.relation.ispartofJACC: Cardiovascular Interventionsen_US
dc.sourceJacc-Cardiovascular Interventions [ISSN 1936-8798], v. 7 (2), p. 212-221, (Febrero 2014)en_US
dc.subject320501 Cardiologíaen_US
dc.subject320704 Patología cardiovascularen_US
dc.subject321307 Cirugía del corazónen_US
dc.subject.otherCoronary-Artery-Diseaseen_US
dc.subject.otherDrug-Eluting Stenten_US
dc.subject.otherBypass-Surgeryen_US
dc.subject.otherBifurcation Lesionsen_US
dc.subject.otherInterventionen_US
dc.subject.otherStenosisen_US
dc.subject.otherImplantationen_US
dc.subject.otherAngioplastyen_US
dc.subject.otherPredictorsen_US
dc.subject.otherCardiologyen_US
dc.subject.otherBifurcation Lesionen_US
dc.subject.otherDrug-Eluting Stent(S)en_US
dc.subject.otherLeft Mainen_US
dc.subject.otherRestenosisen_US
dc.titleImmediate Results and Long-Term Clinical Outcome of Patients With Unprotected Distal Left Main Restenosis The CORPAL Registry (Cordoba and Las Palmas)en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jcin.2013.06.017en_US
dc.identifier.scopus84894343234-
dc.identifier.isi000331719900023-
dc.contributor.authorscopusid8654250900-
dc.contributor.authorscopusid7202544866-
dc.contributor.authorscopusid7406037925-
dc.contributor.authorscopusid24450657100-
dc.contributor.authorscopusid16067353500-
dc.contributor.authorscopusid7202430759-
dc.contributor.authorscopusid55415591100-
dc.contributor.authorscopusid7005198171-
dc.contributor.authorscopusid7202723590-
dc.contributor.authorscopusid7006785516-
dc.identifier.eissn1876-7605-
dc.description.lastpage221en_US
dc.identifier.issue2-
dc.description.firstpage212en_US
dc.relation.volume7en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid343824-
dc.contributor.daisngid77557-
dc.contributor.daisngid1673863-
dc.contributor.daisngid452208-
dc.contributor.daisngid67522-
dc.contributor.daisngid156230-
dc.contributor.daisngid1825688-
dc.contributor.daisngid831427-
dc.contributor.daisngid74576-
dc.contributor.daisngid476437-
dc.description.numberofpages10en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Ojeda, S-
dc.contributor.wosstandardWOS:Pan, M-
dc.contributor.wosstandardWOS:Martin, P-
dc.contributor.wosstandardWOS:Mazuelos, F-
dc.contributor.wosstandardWOS:de Lezo, JS-
dc.contributor.wosstandardWOS:Romero, M-
dc.contributor.wosstandardWOS:Segura, J-
dc.contributor.wosstandardWOS:Pavlovic, D-
dc.contributor.wosstandardWOS:Medina, A-
dc.contributor.wosstandardWOS:de Lezo, JS-
dc.date.coverdateFebrero 2014en_US
dc.identifier.ulpgcen_US
dc.description.sjr5,249
dc.description.jcr7,345
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.grantfulltextopen-
item.fulltextCon texto completo-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Morfología-
crisitem.author.orcid0000-0002-2378-3242-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameMartín Rodríguez, Patricia-
Colección:Artículos
miniatura
Adobe PDF (1,19 MB)
Vista resumida

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.